; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) is focused on developing therapeutics that address unmet medical needs in women’s health.  We are advancing a product pipeline leveraging proprietary  drug delivery technologies for targeted, intravaginal drug delivery.  We expect this delivery approach can provide effective singular and combination treatment options with local delivery to target organs, reduced side effects, and improved compliance -- all to better meet patient needs.


CRINONE® (progesterone gel) is Juniper’s most successful product developed to date and our single largest revenue source. Commercially available in over 90 countries around the world, Crinone is marketed by Merck KGaA, Darmstadt, Germany, outside the U.S. and by Allergan, Inc. in the U.S.